Document Detail


Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study.
MedLine Citation:
PMID:  22814775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This study sought to evaluate the safety and efficacy of second-generation drug-eluting stents (DES) for patients with unprotected left main coronary artery (ULMCA) stenosis.
BACKGROUND: The clinical benefit of second-generation DES for ULMCA stenosis has not been determined.
METHODS: The authors assessed 334 consecutive patients who received everolimus-eluting stents (EES) for ULMCA stenosis between 2009 and 2010. The 18-month incidence rates of major adverse cardiac or cerebrovascular events (MACCE), including death, myocardial infarction (MI), stroke, or ischemia-driven target vessel revascularization (TVR), were compared with those of a randomized study comparing patients who received sirolimus-eluting stents (SES) (n = 327) or coronary artery bypass grafts (CABG) (n = 272).
RESULTS: EES (8.9%) showed a comparable incidence of MACCE as SES (10.8%; adjusted hazard ratio [aHR] of EES: 0.84; 95% confidence interval [CI]: 0.51 to 1.40; p = 0.51) and CABG (6.7%, aHR of EES: 1.40; 95% CI: 0.78 to 2.54; p = 0.26). The composite incidence of death, MI, or stroke also did not differ among patients receiving EES (3.3%), SES (3.7%; aHR of EES: 0.63; 95% CI: 0.27 to 1.47; p = 0.29), and CABG (4.8%; aHR of EES: 0.67; 95% CI: 0.29 to 1.54; p = 0.34). However, the incidence of ischemia-driven TVR in the EES group (6.5%) was higher than in the CABG group (2.6%, aHR of EES: 2.77; 95% CI: 1.17 to 6.58; p = 0.02), but comparable to SES (8.2%, aHR of EES: 1.14; 95% CI: 0.64 to 2.06; p = 0.65). Angiographic restenosis rates were similar in the SES and EES groups (13.8% vs. 9.2%, p = 0.16).
CONCLUSIONS: Second-generation EES had a similar 18-month risk of MACCE for ULMCA stenosis as first-generation SES or CABG.
Authors:
Young-Hak Kim; Duk-Woo Park; Jung-Min Ahn; Sung-Cheol Yun; Hae Geun Song; Jong-Young Lee; Won-Jang Kim; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Yangsoo Jang; Myung-Ho Jeong; Hyo-Soo Kim; Seung-Ho Hur; Seung-Woon Rha; Do-Sun Lim; Sung-Ho Her; Ki Bae Seung; In-Whan Seong; Seung-Jung Park;
Related Documents :
9294785 - Differences in generalist and specialist physicians' knowledge and use of angiotensin-c...
10825 - Medical problems of surgical patients. hypertension and ischaemic heart disease.
22291735 - Predictors of coronary intervention-related myocardial infarction in stable angina pati...
8096675 - Controlled trials with beta blockers in heart failure: metoprolol as the prototype.
18490325 - Partial ventricular septal defect (pacman heart).
15053185 - Ventricular assist devices as destination therapy.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  5     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-20     Completed Date:  2012-12-07     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  708-17     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01348022
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Confidence Intervals
Coronary Artery Bypass
Coronary Restenosis / drug therapy*,  surgery,  therapy
Coronary Vessels / pathology
Drug-Eluting Stents*
Female
Humans
Immunosuppressive Agents / administration & dosage,  therapeutic use*
Incidence
Male
Middle Aged
Risk
Sirolimus / administration & dosage,  analogs & derivatives*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 159351-69-6/everolimus; W36ZG6FT64/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimizing outcomes during left main percutaneous coronary intervention with intravascular ultrasoun...
Next Document:  Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry...